Verrica to present VP-315 basal cell carcinoma data at dermatology meeting

May 5, 2026 4:06 PM

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) will present Phase 2 clinical data for its VP-315 treatment at the 2026 Society for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found